JP2005512976A - Ｒｎａ干渉により線維化疾患を処置するための医薬 - Google Patents
Ｒｎａ干渉により線維化疾患を処置するための医薬 Download PDFInfo
- Publication number
- JP2005512976A JP2005512976A JP2003537650A JP2003537650A JP2005512976A JP 2005512976 A JP2005512976 A JP 2005512976A JP 2003537650 A JP2003537650 A JP 2003537650A JP 2003537650 A JP2003537650 A JP 2003537650A JP 2005512976 A JP2005512976 A JP 2005512976A
- Authority
- JP
- Japan
- Prior art keywords
- dsrna
- type
- strand
- nucleotides
- chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 201000010099 disease Diseases 0.000 title claims abstract description 29
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims abstract description 29
- 230000003176 fibrotic effect Effects 0.000 title claims abstract description 28
- 238000012228 RNA interference-mediated gene silencing Methods 0.000 title claims abstract description 10
- 230000009368 gene silencing by RNA Effects 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 title claims description 38
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 45
- 230000015572 biosynthetic process Effects 0.000 claims abstract description 33
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims abstract description 28
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims abstract description 28
- 210000002744 extracellular matrix Anatomy 0.000 claims abstract description 28
- 230000014509 gene expression Effects 0.000 claims abstract description 21
- 239000003795 chemical substances by application Substances 0.000 claims abstract description 18
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 14
- 229920002477 rna polymer Polymers 0.000 claims abstract description 13
- 239000002773 nucleotide Substances 0.000 claims description 31
- 125000003729 nucleotide group Chemical group 0.000 claims description 31
- 108010050808 Procollagen Proteins 0.000 claims description 25
- 230000000295 complement effect Effects 0.000 claims description 19
- 238000001802 infusion Methods 0.000 claims description 16
- 238000002347 injection Methods 0.000 claims description 16
- 239000007924 injection Substances 0.000 claims description 16
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 14
- 210000004024 hepatic stellate cell Anatomy 0.000 claims description 14
- 239000003094 microcapsule Substances 0.000 claims description 13
- 239000002088 nanocapsule Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 9
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 claims description 9
- 210000001519 tissue Anatomy 0.000 claims description 9
- 108010035532 Collagen Proteins 0.000 claims description 8
- 102000008186 Collagen Human genes 0.000 claims description 8
- 239000000872 buffer Substances 0.000 claims description 8
- 229920001436 collagen Polymers 0.000 claims description 8
- 239000002502 liposome Substances 0.000 claims description 8
- 210000000651 myofibroblast Anatomy 0.000 claims description 7
- 230000037406 food intake Effects 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- 102000008490 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Human genes 0.000 claims description 5
- 108010020504 2-Oxoglutarate 5-Dioxygenase Procollagen-Lysine Proteins 0.000 claims description 5
- 102000002734 Collagen Type VI Human genes 0.000 claims description 5
- 108010043741 Collagen Type VI Proteins 0.000 claims description 5
- 108090000630 Oncostatin M Proteins 0.000 claims description 5
- 102000004140 Oncostatin M Human genes 0.000 claims description 5
- 102000004079 Prolyl Hydroxylases Human genes 0.000 claims description 5
- 108010043005 Prolyl Hydroxylases Proteins 0.000 claims description 5
- 108010003894 Protein-Lysine 6-Oxidase Proteins 0.000 claims description 5
- 102000004669 Protein-Lysine 6-Oxidase Human genes 0.000 claims description 5
- 210000000234 capsid Anatomy 0.000 claims description 5
- 238000009472 formulation Methods 0.000 claims description 5
- 238000007912 intraperitoneal administration Methods 0.000 claims description 5
- 238000001990 intravenous administration Methods 0.000 claims description 5
- 238000004519 manufacturing process Methods 0.000 claims description 5
- 210000000056 organ Anatomy 0.000 claims description 5
- 108010069514 Cyclic Peptides Proteins 0.000 claims description 4
- 102000001189 Cyclic Peptides Human genes 0.000 claims description 4
- 108010018907 Gly-Arg-Gly-Asp-Ser-Pro-Cys Proteins 0.000 claims description 4
- 101000777550 Homo sapiens CCN family member 2 Proteins 0.000 claims description 4
- 102000018967 Platelet-Derived Growth Factor beta Receptor Human genes 0.000 claims description 4
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 4
- 102000014172 Transforming Growth Factor-beta Type I Receptor Human genes 0.000 claims description 4
- 108010011702 Transforming Growth Factor-beta Type I Receptor Proteins 0.000 claims description 4
- 102000004060 Transforming Growth Factor-beta Type II Receptor Human genes 0.000 claims description 4
- 108010082684 Transforming Growth Factor-beta Type II Receptor Proteins 0.000 claims description 4
- 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
- 230000003247 decreasing effect Effects 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000035876 healing Effects 0.000 claims description 4
- 210000003734 kidney Anatomy 0.000 claims description 4
- 210000003292 kidney cell Anatomy 0.000 claims description 4
- 210000005229 liver cell Anatomy 0.000 claims description 4
- 210000005265 lung cell Anatomy 0.000 claims description 4
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 4
- 231100000241 scar Toxicity 0.000 claims description 4
- 230000036573 scar formation Effects 0.000 claims description 4
- 210000004927 skin cell Anatomy 0.000 claims description 4
- 239000011780 sodium chloride Substances 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 230000037396 body weight Effects 0.000 claims description 3
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims description 2
- 201000002793 renal fibrosis Diseases 0.000 claims description 2
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 claims 3
- 102100031168 CCN family member 2 Human genes 0.000 claims 3
- 108091005735 TGF-beta receptors Proteins 0.000 claims 3
- 102000016715 Transforming Growth Factor beta Receptors Human genes 0.000 claims 3
- 206010023421 Kidney fibrosis Diseases 0.000 claims 2
- 239000002775 capsule Substances 0.000 claims 2
- 229920002521 macromolecule Polymers 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 44
- 108010039419 Connective Tissue Growth Factor Proteins 0.000 description 17
- 102000015225 Connective Tissue Growth Factor Human genes 0.000 description 14
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 10
- 239000002299 complementary DNA Substances 0.000 description 7
- 238000001890 transfection Methods 0.000 description 7
- 108020004414 DNA Proteins 0.000 description 6
- 241000700159 Rattus Species 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 238000003556 assay Methods 0.000 description 5
- 239000006143 cell culture medium Substances 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 210000002950 fibroblast Anatomy 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- 102000053602 DNA Human genes 0.000 description 4
- 102000015736 beta 2-Microglobulin Human genes 0.000 description 4
- 108010081355 beta 2-Microglobulin Proteins 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 108090000765 processed proteins & peptides Proteins 0.000 description 4
- 235000018102 proteins Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 101100505328 Colletotrichum trifolii CTG1 gene Proteins 0.000 description 3
- 241000711549 Hepacivirus C Species 0.000 description 3
- 101000964562 Homo sapiens Zinc finger FYVE domain-containing protein 9 Proteins 0.000 description 3
- 108010038512 Platelet-Derived Growth Factor Proteins 0.000 description 3
- 102000010780 Platelet-Derived Growth Factor Human genes 0.000 description 3
- 102100040801 Zinc finger FYVE domain-containing protein 9 Human genes 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 238000003786 synthesis reaction Methods 0.000 description 3
- 238000003146 transient transfection Methods 0.000 description 3
- 108020000948 Antisense Oligonucleotides Proteins 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- 101000812677 Homo sapiens Nucleotide pyrophosphatase Proteins 0.000 description 2
- 102100039306 Nucleotide pyrophosphatase Human genes 0.000 description 2
- 102000046299 Transforming Growth Factor beta1 Human genes 0.000 description 2
- 102000011117 Transforming Growth Factor beta2 Human genes 0.000 description 2
- 101800002279 Transforming growth factor beta-1 Proteins 0.000 description 2
- 101800000304 Transforming growth factor beta-2 Proteins 0.000 description 2
- 102000056172 Transforming growth factor beta-3 Human genes 0.000 description 2
- 108090000097 Transforming growth factor beta-3 Proteins 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000000074 antisense oligonucleotide Substances 0.000 description 2
- 238000012230 antisense oligonucleotides Methods 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012894 fetal calf serum Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 238000012332 laboratory investigation Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- KZDCMKVLEYCGQX-UDPGNSCCSA-N 2-(diethylamino)ethyl 4-aminobenzoate;(2s,5r,6r)-3,3-dimethyl-7-oxo-6-[(2-phenylacetyl)amino]-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid;hydrate Chemical compound O.CCN(CC)CCOC(=O)C1=CC=C(N)C=C1.N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 KZDCMKVLEYCGQX-UDPGNSCCSA-N 0.000 description 1
- 108091027075 5S-rRNA precursor Proteins 0.000 description 1
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 1
- 206010008909 Chronic Hepatitis Diseases 0.000 description 1
- 208000032544 Cicatrix Diseases 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- 102000016942 Elastin Human genes 0.000 description 1
- 108010014258 Elastin Proteins 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 108060002716 Exonuclease Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920002683 Glycosaminoglycan Polymers 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 229920002730 Poly(butyl cyanoacrylate) Polymers 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 101100219980 Rattus norvegicus Ccn2 gene Proteins 0.000 description 1
- 108091081021 Sense strand Proteins 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000003510 anti-fibrotic effect Effects 0.000 description 1
- 230000000692 anti-sense effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 239000004621 biodegradable polymer Substances 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 238000010170 biological method Methods 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229920002549 elastin Polymers 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 102000013165 exonuclease Human genes 0.000 description 1
- 102000036444 extracellular matrix enzymes Human genes 0.000 description 1
- 108091007167 extracellular matrix enzymes Proteins 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 230000009760 functional impairment Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 210000003494 hepatocyte Anatomy 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 238000010899 nucleation Methods 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000004033 plastic Substances 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 239000003161 ribonuclease inhibitor Substances 0.000 description 1
- 230000037387 scars Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 210000004500 stellate cell Anatomy 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1136—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against growth factors, growth regulators, cytokines, lymphokines or hormones
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/50—Physical structure
- C12N2310/53—Physical structure partially self-complementary or closed
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Biochemistry (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10155280 | 2001-10-26 | ||
| DE10158411 | 2001-11-29 | ||
| DE10160151A DE10160151A1 (de) | 2001-01-09 | 2001-12-07 | Verfahren zur Hemmung der Expression eines vorgegebenen Zielgens |
| PCT/EP2002/000152 WO2002055693A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens |
| PCT/EP2002/000151 WO2002055692A2 (de) | 2001-01-09 | 2002-01-09 | Verfahren zur hemmung der expression eines zielgens und medikament zur therapie einer tumorerkrankung |
| PCT/EP2002/011972 WO2003035083A1 (de) | 2001-10-26 | 2002-10-25 | Medikament zur behandlung einer fibrotischen erkrankung durch rna interferenz |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005512976A true JP2005512976A (ja) | 2005-05-12 |
| JP2005512976A5 JP2005512976A5 (enExample) | 2006-03-09 |
Family
ID=39189390
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2003537650A Pending JP2005512976A (ja) | 2001-10-26 | 2002-10-25 | Ｒｎａ干渉により線維化疾患を処置するための医薬 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20080070856A1 (enExample) |
| JP (1) | JP2005512976A (enExample) |
| CN (1) | CN1604783A (enExample) |
| WO (2) | WO2003035083A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2013531487A (ja) * | 2010-06-02 | 2013-08-08 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 肝線維症治療用組成物および肝線維症の治療法 |
| JP2013532952A (ja) * | 2010-03-24 | 2013-08-22 | アールエックスアイ ファーマシューティカルズ コーポレーション | 皮膚および線維症適用におけるｒｎａ干渉 |
| US9303259B2 (en) | 2008-09-22 | 2016-04-05 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
| US10184124B2 (en) | 2010-03-24 | 2019-01-22 | Phio Pharmaceuticals Corp. | RNA interference in ocular indications |
| WO2024262593A1 (ja) * | 2023-06-22 | 2024-12-26 | 公益財団法人川崎市産業振興財団 | 核酸の血中安定性を向上させ、標的化効率を向上させる方法 |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE19956568A1 (de) | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| DE10100586C1 (de) | 2001-01-09 | 2002-04-11 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines Ziegens |
| US7829693B2 (en) | 1999-11-24 | 2010-11-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US7423142B2 (en) | 2001-01-09 | 2008-09-09 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US8546143B2 (en) | 2001-01-09 | 2013-10-01 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of a target gene |
| US7767802B2 (en) | 2001-01-09 | 2010-08-03 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting expression of anti-apoptotic genes |
| US7745418B2 (en) | 2001-10-12 | 2010-06-29 | Alnylam Pharmaceuticals, Inc. | Compositions and methods for inhibiting viral replication |
| DE10163098B4 (de) | 2001-10-12 | 2005-06-02 | Alnylam Europe Ag | Verfahren zur Hemmung der Replikation von Viren |
| DE10202419A1 (de) | 2002-01-22 | 2003-08-07 | Ribopharma Ag | Verfahren zur Hemmung der Expression eines durch eine Chromosomen-Aberration entstandenen Zielgens |
| EP1486564A1 (de) * | 2003-06-13 | 2004-12-15 | Ribopharma AG | SiRNA mit erhöhter Stabilität in Serum |
| ES2761262T3 (es) | 2003-06-13 | 2020-05-19 | Alnylam Europe Ag | Acido ribonucleico bicatenario con elevada eficacia en un organismo |
| US20070004657A1 (en) * | 2003-11-17 | 2007-01-04 | Orna Mor | Diagnosis and treatment of kidney fibrosis and other fibrotic diseases |
| WO2005053725A2 (en) * | 2003-11-26 | 2005-06-16 | The Queen's University Of Belfast | Cancer treatment |
| JP4543189B2 (ja) * | 2004-03-10 | 2010-09-15 | 学校法人日本医科大学 | ＴＧＦβ１レセプターＩＩ型に対するＲＮＡｉとして作用するＲＮＡ配列 |
| FR2898908A1 (fr) | 2006-03-24 | 2007-09-28 | Agronomique Inst Nat Rech | Procede de preparation de cellules aviaires differenciees et genes impliques dans le maintien de la pluripotence |
| WO2010021720A1 (en) | 2008-08-19 | 2010-02-25 | Nektar Therapeutics | Conjugates of small-interfering nucleic acids |
| US8946172B2 (en) * | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| KR101877698B1 (ko) | 2008-08-25 | 2018-07-12 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | 결합 조직 성장 인자에 대한 안티센스 올리고뉴클레오타이드 및 그의 용도 |
| CN102666587A (zh) | 2009-07-02 | 2012-09-12 | 菲布罗根有限公司 | 用于治疗肌营养不良的方法 |
| WO2011035065A1 (en) | 2009-09-17 | 2011-03-24 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
| US20120244169A1 (en) | 2009-11-06 | 2012-09-27 | Fibrogen, Inc. | Treatment for Radiation-Induced Disorders |
| AR083445A1 (es) | 2010-10-14 | 2013-02-27 | Univ Mie | siARN CONTRA LA FIBROSIS |
| US20140134181A1 (en) | 2010-11-05 | 2014-05-15 | Kenneth E. Lipson | Treatment Method For Lung Remodeling Diseases |
| EP2670411B1 (en) | 2011-02-02 | 2019-04-10 | Excaliard Pharmaceuticals, Inc. | Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars |
| US10337009B2 (en) | 2014-12-15 | 2019-07-02 | Bonac Corporation | Single-stranded nucleic acid molecule for inhibiting TGF-β1 expression |
| WO2017100193A1 (en) | 2015-12-10 | 2017-06-15 | Fibrogen, Inc. | Methods for treatment of motor neuron diseases |
| KR102666000B1 (ko) * | 2016-07-29 | 2024-05-14 | 서울대학교 산학협력단 | cFLIP siRNA를 포함하는 인터페론 베타 저항성 암 질환 치료용 또는 감작용 조성물 |
| CN109432047B (zh) * | 2018-10-29 | 2021-07-20 | 中国药科大学 | 一种逆转肺纤维化纳米制剂及其制备方法 |
| US20200369759A1 (en) | 2019-05-23 | 2020-11-26 | Fibrogen, Inc. | Methods of treatment of muscular dystrophies |
| CN112843253B (zh) * | 2021-01-13 | 2023-07-14 | 上海交通大学 | 一种基因/药物复合脂质制剂及其制备方法和用途 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001036646A1 (en) * | 1999-11-19 | 2001-05-25 | Cancer Research Ventures Limited | Inhibiting gene expression with dsrna |
| WO2001075164A2 (en) * | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU6984594A (en) * | 1993-06-15 | 1995-01-17 | Hun Taeg Chung | Anti-sense oligodeoxynucleotide to fibrogenic cytokines and use thereof |
| DE19631919C2 (de) * | 1996-08-07 | 1998-07-16 | Deutsches Krebsforsch | Anti-Sinn-RNA mit Sekundärstruktur |
| US6242569B1 (en) * | 1997-02-05 | 2001-06-05 | Tularik, Inc. | Regulators of apoptosis |
| DE19713393C2 (de) * | 1997-04-01 | 2002-12-05 | Apotech Res & Dev Ltd | Flip-Gen und Flip-Protein |
| US6506559B1 (en) * | 1997-12-23 | 2003-01-14 | Carnegie Institute Of Washington | Genetic inhibition by double-stranded RNA |
| AU4411499A (en) * | 1998-06-05 | 1999-12-20 | Human Genome Sciences, Inc. | Connective tissue growth factor-4 |
| DE69832204T2 (de) * | 1998-10-08 | 2006-07-27 | Stichting Voor De Technische Wetenschappen | Auf peptiden basierende trägervorrichtungen für stellatzellen |
| WO2000027868A2 (en) * | 1998-11-06 | 2000-05-18 | Fibrogen, Inc. | Connective tissue growth factor (ctgf) and methods of use |
| AU775391B2 (en) * | 1998-12-14 | 2004-07-29 | Fibrogen, Inc. | Connective tissue growth factor fragments and methods and uses thereof |
| DE19956568A1 (de) * | 1999-01-30 | 2000-08-17 | Roland Kreutzer | Verfahren und Medikament zur Hemmung der Expression eines vorgegebenen Gens |
| US6436909B1 (en) * | 1999-09-17 | 2002-08-20 | Isis Pharmaceuticals, Inc. | Antisense inhibition of transforming growth factor-β expression |
| CZ302719B6 (cs) * | 2000-12-01 | 2011-09-21 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Izolovaná molekula dvouretezcové RNA, zpusob její výroby a její použití |
-
2002
- 2002-10-25 WO PCT/EP2002/011972 patent/WO2003035083A1/de not_active Ceased
- 2002-10-25 WO PCT/EP2002/011968 patent/WO2003035868A1/de not_active Ceased
- 2002-10-25 JP JP2003537650A patent/JP2005512976A/ja active Pending
- 2002-10-25 CN CNA028251636A patent/CN1604783A/zh active Pending
-
2007
- 2007-05-11 US US11/747,549 patent/US20080070856A1/en not_active Abandoned
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2001036646A1 (en) * | 1999-11-19 | 2001-05-25 | Cancer Research Ventures Limited | Inhibiting gene expression with dsrna |
| WO2001075164A2 (en) * | 2000-03-30 | 2001-10-11 | Whitehead Institute For Biomedical Research | Rna sequence-specific mediators of rna interference |
Cited By (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9938530B2 (en) | 2008-09-22 | 2018-04-10 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
| US10815485B2 (en) | 2008-09-22 | 2020-10-27 | Phio Pharmaceuticals Corp. | RNA interference in skin indications |
| US9303259B2 (en) | 2008-09-22 | 2016-04-05 | Rxi Pharmaceuticals Corporation | RNA interference in skin indications |
| KR20210014780A (ko) * | 2010-03-24 | 2021-02-09 | 피오 파마슈티칼스 코프. | 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭 |
| JP2017018109A (ja) * | 2010-03-24 | 2017-01-26 | アールエックスアイ ファーマシューティカルズ コーポレーション | 皮膚および線維症適用におけるｒｎａ干渉 |
| KR101852210B1 (ko) * | 2010-03-24 | 2018-04-25 | 알엑스아이 파마슈티칼스 코포레이션 | 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭 |
| US9963702B2 (en) | 2010-03-24 | 2018-05-08 | Rxi Pharmaceuticals Corporation | RNA interference in dermal and fibrotic indications |
| US10184124B2 (en) | 2010-03-24 | 2019-01-22 | Phio Pharmaceuticals Corp. | RNA interference in ocular indications |
| US10662430B2 (en) | 2010-03-24 | 2020-05-26 | Phio Pharmaceuticals Corp. | RNA interference in ocular indications |
| JP2013532952A (ja) * | 2010-03-24 | 2013-08-22 | アールエックスアイ ファーマシューティカルズ コーポレーション | 皮膚および線維症適用におけるｒｎａ干渉 |
| US10913948B2 (en) | 2010-03-24 | 2021-02-09 | Phio Pharmaceuticals Corp. | RNA interference in dermal and fibrotic indications |
| KR102453078B1 (ko) * | 2010-03-24 | 2022-10-11 | 피오 파마슈티칼스 코프. | 진피 및 섬유증성 적응증에서의 ｒｎａ 간섭 |
| US11584933B2 (en) | 2010-03-24 | 2023-02-21 | Phio Pharmaceuticals Corp. | RNA interference in ocular indications |
| JP2017074045A (ja) * | 2010-06-02 | 2017-04-20 | アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | 肝線維症治療用組成物および肝線維症の治療法 |
| JP2013531487A (ja) * | 2010-06-02 | 2013-08-08 | アルナイラム ファーマシューティカルズ， インコーポレイテッド | 肝線維症治療用組成物および肝線維症の治療法 |
| WO2024262593A1 (ja) * | 2023-06-22 | 2024-12-26 | 公益財団法人川崎市産業振興財団 | 核酸の血中安定性を向上させ、標的化効率を向上させる方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CN1604783A (zh) | 2005-04-06 |
| US20080070856A1 (en) | 2008-03-20 |
| WO2003035083A1 (de) | 2003-05-01 |
| WO2003035868A1 (de) | 2003-05-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2005512976A (ja) | Ｒｎａ干渉により線維化疾患を処置するための医薬 | |
| US20050119202A1 (en) | Medicament to treat a fibrotic disease | |
| JP2023103244A5 (enExample) | ||
| KR102002771B1 (ko) | Hsp47 발현의 조절을 촉진하기 위한 레티노이드-리포좀 | |
| CN102803284B (zh) | 用于miRNA抑制剂和模拟物的化学修饰基序 | |
| US8647820B2 (en) | Circular dumbbell decoy oligodeoxynucleotides (CDODN) containing DNA bindings sites of transcription | |
| JPH11501510A (ja) | Ｂリンパ球において発現されたアンチセンス転写産物およびその活性を阻害するために有用な合成オリゴヌクレオチド | |
| CN104540527A (zh) | Mir-15微小rna家族的抑制剂 | |
| WO2010120969A1 (en) | Targeting of the mir-30 family and let-7 family as a treatment for heart disease | |
| KR20180005546A (ko) | 약물이 탑재된 엑소좀 또는 나노베지클을 이용한 약학적 조성물 | |
| JP2013511964A (ja) | ｍｉＲＮＡ−１００を含む医薬組成物ならびに血管増殖および内皮炎症を調節するためのその使用 | |
| CN108251420A (zh) | 抑制人和动物中CTGF基因表达的siRNA、包含其的组合物及其应用 | |
| CN110536965B (zh) | 用于抑制男性型脱发靶基因表达的不对称siRNA | |
| Yao et al. | Nucleic acid nanomaterials-based therapy for osteoarthritis: Progress and prospects | |
| CA2451874C (fr) | Oligonucleotides antisens capables d'inhiber la formation des tubes capillaires par des cellules endotheliales | |
| AU2021275643A1 (en) | Double-stranded oligonucleotide and composition for treating covid-19 containing same | |
| CN117660450A (zh) | 一种miRNA核酸分子、药物组合物及其在制备用于促进组织再生的药物中的应用 | |
| KR101783444B1 (ko) | miR-33-5p 를 이용한 뇌신경세포 보호 물질 스크리닝 방법 | |
| CN108251421A (zh) | 抑制人和动物中COL1A1基因表达的siRNA、包含其的组合物及其应用 | |
| CN108239643A (zh) | 抑制人和动物中TIMP-1基因表达的siRNA、包含其的组合物及其应用 | |
| JP4368936B2 (ja) | 転写ｄｎａ結合部位を含む環状ダンベルデコイオリゴデオキシヌクレオチド（ｃｄｏｄｎ） | |
| US20250144129A1 (en) | Pharmaceutical compositions for preventing or treating liver diseases with fibrosis | |
| CN110066800A (zh) | 一种新化合物及其组合物的应用 | |
| WO1998049287A2 (en) | Antisense oligonucleotides specific for thymidylate synthase | |
| JP2025078002A (ja) | 線維化を伴う肝疾患を予防又は治療するための医薬組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20050829 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20060119 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20090804 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091104 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091111 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091204 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20091211 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20091228 |
|
| A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20100108 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20100406 |